Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129336 · ClinicalTrials.gov registry record · Phase 4
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT01129336 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT01129336, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
Interventions
- DRUG Zoledronic acid
- DRUG Standard Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129336
The ClinicalTrials.gov registry entry for NCT01129336 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zoledronic acid is the first listed.
NCT01129336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129336 about?
NCT01129336 is a clinical study titled "Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients". This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
What is the current status of trial NCT01129336?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2010-06. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01129336?
The interventions under investigation include: Zoledronic acid (DRUG), Standard Therapy (DRUG).
Who is sponsoring clinical trial NCT01129336?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.